The Correlation Of The Sensitivity To NP Chemotherapy In Non-Small Lung Cancer To DNA Repair Gene XRCC1 Polymorphism

BackgroundThe gene polymorphism is used to predict the sensitivity to chemotherapy, which is significant for the individualized treatment of tumor.ObjectiveThis study was to explore the correlations of codon 194 and codon 399 polymorphisms of DNA repair gene X-ray repair cross complementing (XRCC1) to the sensitivity of non-small cell lung cancer (NSCLC) to NP (vinorebine and cisplatin) chemotherapy.MethodsXRCC1 polymorphisms at codon 194 and codon 399 was detected in 164 NSCLC patients using a polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Patients taking NP chemotherapy were evaluated two periods after the treatment, then the correlation of the sensitivity to chemotherapy and polymorphisms was analysed.Results1. Patients with the XRCC1 codon 194 C/T+T/T polymorphisms were 2.038 times more sensitive to the treatment than patients with C/C genotype(P=0.036 ,95%CI=1.044-3.976).2. There was no significant difference for the effective rate to chemotherapy of XRCC1 codon 399G/A polymorhism.3.The effective rate to chemotherapy of the T-A haplotype significantly increased than other haplotype groups(P=0.031) while that of the C-A haplotype significantly decreased than others(P=0.035) using SHEsis analysis software. Conclusion1 .The sensitive for NP chemotherapy in the NSCLC patients who carries XRCC1 194 CT and TT genotypes increased significantly than that of CC genotype.2.XRCC1 codon 194 and codon399 polymorphisms possess clinic application to predict the sensitivity to NP chemotherapy in NSCLC patients.